Sterling Pharma Solutions’ customer, ADC Therapeutics SA, has received FDA approval for the antibody drug conjugate (ADC) Zynlonta (loncastuximab tesirine-lpyl) that its Deeside facility contributed to developing.   Zynlonta has been granted accelerated approval by the FDA for use in adult patients with relapsed or refractory B-cell lymphoma (DLBCL), including DLBCL not otherwise specified (NOS), DLBCL arising from low grade lymphoma and also high-grade B-cell lymphoma, and is now commercially...